Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Licenses Rubicon's Methylation-Detection Tech

NEW YORK (GenomeWeb News) — Abbott has obtained a non-exclusive license to use Rubicon Genomics' MethylPlex methylation-detection technology, which it will use to develop in vitro diagnostics that detect presence or risk of prostate, bladder, and colon cancer, Rubicon said today.

The deal, which was struck as part of an ongoing agreement between the two companies, also grants Abbott a non-exclusive license to use the MethylPlex for screening applications with other diseases, and options to colon cancer biomarkers that it co-developed with Rubicon.

Financial terms of the agreement were not released.

The ongoing collaboration "has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays," Rubicon acting-President and CEO James Koziarz said in a statement.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more